Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pharmasset, Inc.
The generics industry struggled with the prior-year comparison as it saw an expected decline in revenues in the first quarter of 2021, driven by the global impact of the COVID-19 crisis. As a result, the performance of most companies fell short of the numbers reported in Q1 2020. However, a few managed to contradict the trend by reporting growth, either based on the launch of COVID-related drugs or performance in specific geographies.
Mirati executives are still being pushed to defend the safety profile for the KRAS G12C inhibitor adagrasib, which has been seen as a potential disadvantage relative to Amgen’s Lumakras.
TERN-101 showed a superior safety and tolerability profile for lipid levels and pruritis compared to other FXR agonists in a mid-stage study. Terns is now looking to a NASH combo study with its THR beta agonist.
Japan’s Nippon Chemiphar gets a grip on a decline in pharmaceutical sales seen earlier this year, on the back of strong sales of generic drugs launched last year. The company also expects an upward impact from expanded sales of generic drugs achieved through sales channel diversification efforts for its current financial year ending 31 March 2022.